Nimrodi has served as the executive chairman of Accellix since June 2019.
In order to serve its growing list of customers in the cell and gene therapy market, Accellix has recently launched standardized kits such as the T-Cell and Lymphocyte Subset Assays to provide immediate fixed panels for common markers.
These assays are in addition to the growing number of customized assay kits available to Accellix's global customers.
Nimrodi brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical and biotechnology industries.
In his most recent role, Nir served as the Chief Business officer of Intrexon Corp., a leader in synthetic biology.
Intrexon and its partners are among the pioneering companies in the field of immuno-oncology as well as several other gene therapy programmes.
Prior to Intrexon, Nir held several executive roles at Life Technologies (now part of Thermo Fisher).
While at Life, Nir served as chief executive officer and Board Member of Life Technologies Israel, Head of Protein Technologies, as well as vice president and general manager of Food Safety and Animal Health. Prior to his seven years at Life Technologies, he was the CEO of Proneuron Biotechnologies and Mindsense Biosystems.
Earlier in his career, Nir was a director of Finance for Teva Pharmaceuticals.
Accellix is a biotechnology company dedicated to developing and commercialising the Accellix platform to enable its customers in the field of cell and gene therapy to meet their critical QC requirements as they advance life changing therapies benefiting patients worldwide.
Accellix empowers its customers by migrating their existing cell assays to the Accellix platform.
The Accellix platform is a benchtop cytometer operating and reading capillary cartridges integrated with dry reagents. It provides unmatched reproducibility and ease of use for automated multi-parametric cell analysis.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886